Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02)

  • End date
    May 26, 2023
  • participants needed
  • sponsor
    Immunomedics, Inc.
Updated on 26 January 2021
kidney function tests
cancer chemotherapy


This is an open-label, randomized, multicenter Phase 3 study to compare the efficacy and safety of Sacituzumab Govitecan versus TPC in subjects with metastatic or locally recurrent inoperable HR+/HER2- MBC, after failure of at least 2, and no more than 4, prior chemotherapy regimens for metastatic disease.


Approximately 400 eligible subjects will be randomized to one of the following 2 treatment


Investigational Arm:

Sacituzumab Govitecan 10 mg/kg via IV injection administered on Day 1 and Day 8 (21-day cycle).

Control Arm:

Recommended doses and schedules as per NCCN guidelines (with dose modifications if too toxic).

Eribulin; Capecitabine; Gemcitabine; Vinorelbine

Condition Metastatic Breast Cancer, Stage IV Breast Cancer
Treatment Capecitabine, Gemcitabine, Eribulin, Vinorelbine, Sacituzumab govitecan
Clinical Study IdentifierNCT03901339
SponsorImmunomedics, Inc.
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have Metastatic Breast Cancer?
Do you have any of these conditions: Stage IV Breast Cancer or Metastatic Breast Cancer?
Female or male subjects aged 18 years at the time of signing the informed consent form
Documented evidence of hormone receptor-positive HER2-negative (HR+/HER2-) MBC confirmed
Refractory to or relapsed after at least 2, and no more than 4, prior systemic chemotherapy regimens for MBC including
At least 1 prior anticancer hormonal treatment
At least 1 cyclin-dependent kinase inhibitor 4/6 in the metastatic setting
Eligible for one of the chemotherapy options listed in the TPC arm
Documented disease progression after the most recent therapy
Adequate bone marrow function (hemoglobin > 9 g/dL, ANC > 1,500 per mm3, platelets > 100,000 per mm3)
Adequate renal function: calculated creatinine clearance 30 mL/minute according to the Cockcroft and Gault formula
Adequate hepatic function (bilirubin 1.5 IULN, AST and ALT 2.5 x IULN or 5.0 x IULN)
Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta human chorionic gonadotropin [-hCG]

Exclusion Criteria

Previous treatment with Topoisomerase 1 Inhibitors as a free form or as other formulations
History of significant cardiovascular disease or clinically significant ECG abnormality
Patients with Gilbert's disease
Active infection requiring intravenous antibiotic use
Patients with a history of an anaphylactic reaction to irinotecan
Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations
Locally advanced MBC (stage IIIc) in subjects who are candidates for curative intent therapy at the time of study enrollment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note